Amgen, Inc. (AMGN) Shares Sold by Loeb Partners Corp

Loeb Partners Corp trimmed its position in Amgen, Inc. (NASDAQ:AMGN) by 42.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,000 shares of the medical research company’s stock after selling 4,500 shares during the quarter. Loeb Partners Corp’s holdings in Amgen were worth $1,244,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in AMGN. Pillar Pacific Capital Management LLC raised its position in Amgen by 0.5% during the second quarter. Pillar Pacific Capital Management LLC now owns 56,671 shares of the medical research company’s stock valued at $10,461,000 after acquiring an additional 254 shares in the last quarter. Murphy Capital Management Inc. raised its position in Amgen by 2.3% during the third quarter. Murphy Capital Management Inc. now owns 11,285 shares of the medical research company’s stock valued at $2,339,000 after acquiring an additional 254 shares in the last quarter. Fairfield Bush & CO. raised its position in Amgen by 0.8% during the second quarter. Fairfield Bush & CO. now owns 33,934 shares of the medical research company’s stock valued at $6,264,000 after acquiring an additional 260 shares in the last quarter. Advisors Capital Management LLC raised its position in Amgen by 5.8% during the second quarter. Advisors Capital Management LLC now owns 4,737 shares of the medical research company’s stock valued at $874,000 after acquiring an additional 261 shares in the last quarter. Finally, Mutual Advisors LLC raised its position in Amgen by 5.8% during the second quarter. Mutual Advisors LLC now owns 4,814 shares of the medical research company’s stock valued at $889,000 after acquiring an additional 265 shares in the last quarter. Hedge funds and other institutional investors own 77.91% of the company’s stock.

Shares of AMGN opened at $208.25 on Friday. The company has a current ratio of 3.08, a quick ratio of 2.84 and a debt-to-equity ratio of 2.05. The company has a market capitalization of $128.35 billion, a price-to-earnings ratio of 16.55, a price-to-earnings-growth ratio of 2.09 and a beta of 1.37. Amgen, Inc. has a 12 month low of $163.31 and a 12 month high of $210.19.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.45 by $0.24. The firm had revenue of $5.90 billion for the quarter, compared to analyst estimates of $5.78 billion. Amgen had a return on equity of 54.14% and a net margin of 9.44%. The business’s revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the company posted $3.27 earnings per share. Research analysts anticipate that Amgen, Inc. will post 14.24 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 7th. Stockholders of record on Friday, November 16th will be paid a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date is Thursday, November 15th. Amgen’s dividend payout ratio is presently 41.97%.

AMGN has been the subject of several recent research reports. Cann reiterated a “buy” rating and set a $224.00 price target on shares of Amgen in a research report on Monday, October 1st. Jefferies Financial Group reiterated a “buy” rating and set a $220.00 price target on shares of Amgen in a research report on Monday, October 1st. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $234.00 price target for the company in a research report on Monday, October 1st. Oppenheimer reissued a “buy” rating and issued a $224.00 price objective on shares of Amgen in a report on Tuesday, August 28th. Finally, BidaskClub raised Amgen from a “hold” rating to a “buy” rating in a report on Wednesday, September 26th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $204.55.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.com-unik.info/2018/12/01/amgen-inc-amgn-shares-sold-by-loeb-partners-corp.html.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Further Reading: How the Consumer Price Index (CPI) is calculated?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit